Vimarsana
Biggest News Aggregation in the World

Daneng Li News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Daneng Li. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Daneng Li Today - Breaking & Trending Today

Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024 - Vimarsana News

Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024

Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients.Encouraging VAXI...

City of Hope Scientists Present Leading-Edge Research at American Association for Cancer Research (AACR) Annual Meeting - Vimarsana News

City of Hope Scientists Present Leading-Edge Research at American Association for Cancer Research (AACR) Annual Meeting

LOS ANGELES--(BUSINESS WIRE)--Apr 8, 2024--

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 - Vimarsana News

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126

Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced data from its ...

Dr Li on the Use of ADG126 With Pembrolizumab in MSS CRC - Vimarsana News

Dr Li on the Use of ADG126 With Pembrolizumab in MSS CRC

Daneng Li, MD, discusses a study utilizing of ADG126 in combination with pembrolizumab for patients with microsatellite stable colorectal cancer.

Imugene's CF33-hNIS (VAXINIA) & MAST Study Featured at ASCO GI Cancers ... - Vimarsana News

Imugene's CF33-hNIS (VAXINIA) & MAST Study Featured at ASCO GI Cancers ...

Imugene's CF33-hNIS (VAXINIA) & MAST Study Featured at ASCO GI Cancers ...